echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: Analysis of survival rates in breast cancer patients with BRCA2 mutations

    Br J Cancer: Analysis of survival rates in breast cancer patients with BRCA2 mutations

    • Last Update: 2021-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Early breast cancer patients need to choose a treatment option based on tumor characteristics, including tumor size, grade, hormone-like expression status, HER2 expression status, underarm lymph node status, and patient preferences.
    growing evidence that genetic mutations in susceptible genes such as BRCA1 and BRCA2 are also linked to disease.
    previous studies have shown that most breast cancers associated with BRCA2 mutations show ER-positive, while ER-positive is a favorable prognostic factor compared to ER-negative in the general early-stage patient population.
    , however, recent studies have shown that ER-positive and low-level tumor status may not be good predictive of good prognostics in patients with BRCA2 mutations.
    there are no studies to report the effects of various breast cancer treatment strategies on patients with BRCA2 mutations.
    , the study aims to explore the effects of double ovary excision and other treatment strategies on survival rates in patients with BRCA2 mutant breast cancer.
    10-year survival rate of BRCA2 mutant breast cancer patients analyzed 664 female BRCA2 mutant patients with stage I-III breast cancer by combining five different data sets (retrospective and forward-looking) studies.
    from diagnosis to death, subjects were followed for an average of 7.2 years.
    by analyzing the patient's tumor characteristics and cancer treatment records, and identifying relevant survival predictive factors with Cox regression models, and adjusting for other treatments and prognostic characteristics.
    10-year breast cancer survival rate was 78.9 percent for ER-positive patients and 82.3 percent for ER-negative patients.
    10-year breast cancer survival rate was 89.1 per cent for women who under performed a double-sided ovary excision, compared with 59.0 per cent for women who did not have a double-sided ovarian excision.
    -adjusted chemotherapy risk ratio was 0.83.
    10-year survival rate in patients with BRCA2 mutant breast cancer, the study revealed that ER-positive status did not indicate a higher survival rate for women with BRCA2 mutations with breast cancer.
    ovarian excision is associated with a reduced risk of breast cancer death and should be considered in treatment plans.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.